Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

Background and AimMany studies indicated that eltrombopag and romiplostim could improve hematopoietic function in patients with myelodysplastic syndromes (MDS), but their toxicity and efficacy were not known. This meta-analysis aimed to investigate the safety and efficacy of eltrombopag and romiplos...

Full description

Bibliographic Details
Main Authors:	Fanqiao Meng, Xiuqiong Chen, Shunjie Yu, Xiaotong Ren, Zhaoyun Liu, Rong Fu, Lijuan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Oncology
Subjects:	eltrombopag meta-analysis myelodysplastic syndromes romiplostim thrombocytopenia
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.582686/full

Similar Items

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018-11-01)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
by: Wang Eunice S, et al.
Published: (2012-11-01)

Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records
by: Lincy S. Lal, et al.
Published: (2020-10-01)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
by: Cy R. Wilkins, et al.
Published: (2022-03-01)

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
by: Francesco D’Alò, et al.
Published: (2021-04-01)

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice
by: V V PTUSHKIN, et al.
Published: (2018-07-01)

Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
by: Efthymia Vlachaki, et al.
Published: (2011-10-01)

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?
by: Jefri Pratama Susanto
Published: (2016-11-01)

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently
by: Mohamed A. Yassin, et al.
Published: (2023-12-01)

Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
by: Olga S. Levchenkova, et al.
Published: (2023-03-01)

Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description
by: Rodriguez Nuñez Rosa María, et al.
Published: (2020-04-01)

Management of patients with immune thrombocytopenia in the Moscow region
by: S. G. Zakharov, et al.
Published: (2022-11-01)

Immune thrombocytopenia: improving quality of life and patient outcomes
by: Trotter P, et al.
Published: (2018-11-01)

Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura
by: Mehmet Can Uğur, et al.
Published: (2021-08-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
by: Angelica Maria Garzon, et al.
Published: (2015-08-01)

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
by: Demet Çekdemir, et al.
Published: (2019-11-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2018-01-01)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
by: Francesca Palandri, et al.
Published: (2012-06-01)

Evaluation of safety, efficacy and pharmacokinetics of Eltrombopag in patients with chronic immune thrombocytopenia: Meta-analysis of randomized controlled trials Authors
by: Abdullah AL-Dhuraibi, et al.
Published: (2023-06-01)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
by: Gilbert MM, et al.
Published: (2020-07-01)

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

Exploring the Potential of Eltrombopag: Room for More?
by: Francesco Tarantini, et al.
Published: (2022-05-01)

Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag
by: Danish Fazal, et al.
Published: (2010-01-01)

Immune thrombocytopenia and cerebral thrombophlebitis in a patient on eltrombopag: A rare complication
by: Salma Fares, MD, et al.
Published: (2023-06-01)

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey
by: Ayça Koca Yozgat, et al.
Published: (2020-08-01)

Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme
by: Tomás José González-López, et al.
Published: (2023-03-01)

Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
by: Mehmet Baysal, et al.
Published: (2022-02-01)

The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
by: Li Liu, et al.
Published: (2023-12-01)

Missing Cells - A Rare Case of Persisting Thrombocytopenia in Pregnancy With Dengue and Role of Romiplostim in These Cases
by: Ruchita Sinha, et al.
Published: (2023-06-01)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
by: Fernanda Lubiana de Oliveira, et al.
Published: (2023-01-01)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
by: Abdulkadir Erçalışkan, et al.
Published: (2022-11-01)

The Use of High Dose Eltrombopag in the Management of Sepsis-Associated Thrombocytopenia in Critically Ill Patients
by: Hasan Md. Jahidul, et al.
Published: (2019-11-01)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
by: Romain Gellens, et al.
Published: (2018-01-01)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-12-01)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-11-01)

Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy
by: Giuseppe Palumbo, et al.
Published: (2023-12-01)

Eltrombopag-Induced Myelofibrosis in Patients with Adult Immune Thrombocytopenia: Scoping Review
by: Iman Moustafa, et al.
Published: (2019-08-01)